

9 February 2016

**Distinguished Clinician Dr Joe Goldstrich
Joins Zelda Therapeutics' Scientific Advisory Board**

Highlights

- Distinguished clinician, Dr Joe Goldstrich, has joined Zelda's Scientific Advisory Board
- Dr Goldstrich holds over 40 years of clinical medicine experience, including caring for and evaluating thousands of patients receiving medicinal cannabis
- His knowledge and experience in the US medical cannabis industry will be instrumental in shaping Zelda's rigorous scientific research and clinical trials
- Dr Goldstrich joins an established and well credentialed Scientific Advisory Board, supported by extensive research experience of the therapeutic use of medical cannabis
- His appointment aligns with Zelda's strategy to bring together world leading researchers and clinicians to validate the efficacy of medical cannabis in key indications

Gleneagle Gold Limited (ASX:GLN) is pleased to provide an update on behalf of Zelda Therapeutics Pty Ltd ("Zelda"). Zelda has appointed distinguished medical clinician, Dr Joe Goldstrich, to the Company's Scientific Advisory Board with immediate effect.

Dr Goldstrich has a distinguished clinical career in preventive cardiology and nutrition spanning over 40 years. His work includes roles as the National Director of Education and Community Programs for the prestigious American Heart Association, Medical Director at the Pritikin Longevity Center and Medical Director of ProCaps Laboratories, where he designed nutritional supplements based on published scientific studies. He has authored four well respected books on diet, nutrition and preventive cardiology.

He is a strong advocate for the use of medical cannabis and has evaluated over 3,500 patients in the US using cannabis as a fundamental medicine in the management of a variety of medical conditions. His most recent work has focused on the use of cannabis in the clinical management of cancer. He serves on the Board of Directors of the Society of Cannabis Clinicians, a leading US non-profit organisation dedicated to educating physicians about the medical use of cannabis and is their liaison to the California Medical Board.

As a member of the Scientific Advisory Board Dr Goldstrich will be instrumental in shaping the rigorous scientific research and clinical trials that Zelda plans to fund as part of its strategy to become a leading biotechnology company in the emerging medical cannabis sector.

Registered Office:
Level 45, 108 St George's Terrace
Perth WA 6000

Postal Address:
PO Box 7315
Perth WA 6850

T: +61 8 9486 7066 F: +61 8 9486 8066

He joins the Scientific Advisory Board alongside other leading clinical and scientific members:

- Professor Manuel Guzman - Full Professor of Biochemistry and Molecular Biology at Madrid's Complutense University and expert on the molecular mechanisms of action and role of cannabinoids in controlling cell generation and death
- Dr Cristina Sanchez - Assistant Professor at Complutense University, Madrid Spain and specialist in the area of lipid signaling, including cannabinoids in an oncology setting
- Dr Donald Abrams - a cancer and integrative medicine specialist at the UCSF Osher Center for Integrative Medicine at Mount Zion and Chief of Haematology and Oncology at San Francisco General Hospital

Together, they bring a wealth of clinical and scientific knowledge and experience to Zelda as it prepares to invest in a series of high value, low cost and short duration trials in cannabis medicine.

Dr Goldstrich graduated from the University of Texas Southwestern Medical School in 1964. He completed fellowships in diabetes, metabolism, and cardiology and became board certified in the US in internal medicine, cardiovascular disease and clinical lipidology. While completing his medical training, he had the rare privilege to work as part of the team that attended President John F. Kennedy after he was shot in 1963. He lives in Iowa and California, US.

Commenting on the appointment, Zelda Chairman Harry Karelis said:

"We are honoured to have a clinician of Dr Goldstrich's calibre and experience joining the Zelda team. With a medical career spanning over 40 years and his evidence-based evaluations of the benefits that thousands of patients receive from medical cannabis treatments, his guidance will be instrumental in helping to place Zelda at the forefront of cannabis-based medicines."

Dr Joe Goldstrich commented:

"Whilst the medical cannabis industry is well established in the US and Europe, the medicine is still wildly under-researched. It is for this reason I am delighted to join the Scientific Advisory Board of Zelda Therapeutics as they look to validate the use of medical cannabis in treating a variety of ailments and serious illnesses through extensive scientific research and clinical trials."

As announced on 9 December 2015, Gleneagle Gold has entered into an agreement to acquire 100% of the issued capital of Zelda Therapeutics, subject to shareholder approval. The acquisition is expected to complete in April 2016, however this timetable may change.

Ends



For more information:

Harry Karelis
Chairman
Zelda Therapeutics Pty Ltd
M: +61 413 056 328
E: hkarelis@titancapitalpartners.com.au

Matthew Wu
Media & Capital Partners
M: 0433 634 706
E: matthew.wu@mcpartners.com.au

About Zelda Therapeutics

Zelda Therapeutics is an Australian biotechnology company that brings together some of the world's leading researchers and clinicians active in the study and use of medicinal cannabis to treat a variety of ailments.

With an initial focus on cancer and skin conditions, we believe that by investing in rigorous scientific research and clinical trials we can generate significant value for all stakeholders as the world re-acquaints itself with this ancient medicine.

www.zeldatherapeutics.com